Clinical trials: Immune-related Adverse Event
Asthma Aspirin-sensitive, ASA Intolerant Asthma
Challenge Test for Acetylsalicylic Acid Hypersensitivity
The investigators want to find new challenge test for Acetylsalicylic hypersensitivity / Aspirin hypersensitivity. The investigators suggest that this new test will be as efficient as the already established protocols in terms of…
- Conditions
- Asthma Aspirin-sensitive, ASA Intolerant Asthma, Asthma, Aspirin-Induced, Asthma, Nasal Polyps, and Aspirin Intolerance
- Trial name
- NCT01681615
- Testing
- Acetylsalicylate, Isotonic NaCl
- Where
- 2 sites in Norway
- Volunteers
- 50 people
- Sponsor
- Helse Stavanger HF
Immune Checkpoint Inhibitor-associated Myocarditis
ATROPOS: Survival Analysis of ICI-associated Myocarditis
ATROPOS is an international, registry-based observational study of cancer patients with immune checkpoint inhibitor-associated myocarditis (ICI-M).
- Trial name
- ATROPOS (NCT07633587)
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Acute Liver Failure, Acute Liver Injury
Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury
This Phase 2a clinical study is designed to provide data on OCR-002 in patients with acute liver failure/acute liver injury (ALF/ALI) in regard to: safety and tolerability; metabolism of the compound to glutamine and…
- Trial name
- STOP-ALF (NCT01548690)
- Testing
- Ornithine Phenylacetate
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- William Lee
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
This phase II trial tests how well itacitinib works in in patients with immune related adverse events (irAEs) arising from immune checkpoint inhibitors (ICI) that do not respond to steroids (steroid refractory).
- Trial name
- NCT05660421
- Testing
- Itacitinib, Corticosteroid, Endoscopic Procedure
- Sponsor
- Douglas Johnson
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004132
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Lymphoma, Non-Hodgkin, Hodgkin Lymphoma
Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma
Treatments-related cardiotoxicity is a critical issue in long term lymphoma survivors, particularly at young age, and its early identification is important to prevent clinically relevant cardiac events.
- Conditions
- Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Toxicity, Cardiac
- Trial name
- Cardiocare (NCT03480087)
- Where
- Italy
- Volunteers
- 118 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
RATIONALE: Biological therapies, such as antithymocyte globulin may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00317798
- Testing
- anti-thymocyte globulin, sirolimus
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Rochester
Stevens - Johnson Syndrome
G-CSF in the Treatment of Toxic Epidermal Necrolysis
NeupoNET aims to evaluate interest of G-CSF in the treatment of Toxic Epidermal necrolysis. This is a prospective randomized controlled trial.
- Trial name
- NeupoNET (NCT02739295)
- Testing
- recombinant granulocyte - colony stimulating factor, NaCl 0.9%
- Where
- 2 sites in Belgium
- Volunteers
- 10 people
- Sponsor
- University of Liege
Toxic Epidermal Necrolysis
Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis
The primary objectives of this study are to investigate the efficacy and safety of topical steroid ointment (clobetasol 0.05%) for the treatment of the cutaneous manifestations of toxic epidermal necrolysis (TEN).
- Trial name
- TEN (NCT02319616)
- Testing
- Clobetasol 0.05% ointment
- Where
- United States
- Sponsor
- University of California, Davis
Human Immunodeficiency Virus Infection (HIV), HIV-1 Infection in Adults
Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.
The RELATIVITY study is a nationwide, multicenter, ambispective observational cohort evaluating the long-term effectiveness, safety, persistence, and tolerability of long-acting injectable cabotegravir plus rilpivirine (CAB+RPV…
- Trial name
- NCT07703748
- Where
- Spain
- Volunteers
- 3,346 people
- Sponsor
- FUNDACIÓN HOSPITAL UNIVERSITARIO INFANTA LEONOR Y DEL HOSPITAL UNIVERSITARIO DEL SURESTE
Cardiotoxicity, Breast Cancer
PROactive Evaluation of Function to Avoid CardioToxicity
This study is intended to evaluate the ability of an intramyocardial strain analysis package with cardiac MRI to assist in the early detection and management of cardiotoxicity from therapeutics used to treat cancer.
- Conditions
- Cardiotoxicity, Breast Cancer, Lymphoma, Sarcoma
- Trial name
- PROACT (NCT03862131)
- Testing
- MyoStrain®
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Washington University School of Medicine
Pneumonitis, Interstitial, Immunotherapy
A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade
The main goal of this prospective non-interventional exploratory monocentric study is to characterize the immune cell composition of bronchoalveolar lavage (BAL) fluid from cancer patients experiencing cancer therapy-induced…
- Conditions
- Pneumonitis, Interstitial, Immunotherapy, Immune-related Adverse Events
- Trial name
- NCT04807127
- Testing
- Immune checkpoint blockade, Targeted therapy, Radiotherapy
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Melanoma Stage III, Melanoma Stage IV
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV
- Trial name
- NCT04305145
- Testing
- Infliximab, Methylprednisolone, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Myocarditis
AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS
Immune-checkpoint-inhibitors (ICI) have revolutionized treatment for about 20 cancer types. They unleash anti-tumor immune responses.
- Trial name
- ACHLYS (NCT05195645)
- Testing
- Abatacept 250 MG
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphoma Cancer, Breast Cancer
Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity
This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or…
- Conditions
- Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma
- Trial name
- NCT07838649
- Testing
- 68Ga-Galmydar, PET/MRI, 18F-FDG
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Washington University School of Medicine
Immune-related Adverse Event, Diarrhea
Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)
The study team's principal interest is to address the question, "Will prophylactic treatment with mesalamine reduce the incidence and severity of immune-related diarrhea occurring secondarily to treatment with ipi/nivo?"
- Conditions
- Immune-related Adverse Event, Diarrhea, Advanced Melanoma, Advanced Rectal Carcinoma
- Trial name
- IMPACT 1 (NCT05663775)
- Testing
- Mesalamine
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- AHS Cancer Control Alberta
Immune Related Adverse Events, Immune-Mediated Hepatitis
Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids
This study evaluates the effectiveness of low-dose corticosteroids in managing grade 2-3 immune-related hepatitis in cancer patients treated with immune checkpoint inhibitors.
- Conditions
- Immune Related Adverse Events, Immune-Mediated Hepatitis, Cancer
- Trial name
- MIRA-HEP (NCT07167251)
- Testing
- Low-dose corticosteroids for immune-related hepatitis grade 3, Low-dose corticosteroids for immune-related hepatitis grade 2
- Where
- 2 sites in Switzerland, United Kingdom
- Volunteers
- 63 people
- Sponsor
- University Hospital, Basel, Switzerland
Chronic Conjunctivitis, Stevens-Johnson Syndrome
Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis.
A phase IIa, open label, non controlled clinical trial to assess the feasibility and safety of allogeneic adipose-derived mesenchymal stem cells (ASC) in the treatment of cicatricial conjunctivitis associated with Lyell's…
- Conditions
- Chronic Conjunctivitis, Stevens-Johnson Syndrome, Lyell Syndrome, Pemphigoid
- Trial name
- CELOPHIN (NCT05520086)
- Testing
- Single Dose, Double Dose
- Where
- 8 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Cancer
Immune Checkpoint Inhibitors Rechallenge After Immune-related Adverse Events
Although immune checkpoint inhibitors (ICIs) have proved effective in treating many cancers, patients receiving ICIs may experience immune-related adverse events (irAEs).
- Trial name
- 19-916 (NCT04169503)
- Testing
- Immune Checkpoint Modulator
- Where
- France
- Volunteers
- 17,562 people
- Sponsor
- University Hospital, Caen
ALL, Childhood, Pediatric Cancer
Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia
A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL).
- Conditions
- ALL, Childhood, Pediatric Cancer, Toxicity, Drug, Adverse Drug Event
- Trial name
- MPGx-INDALL (NCT05512169)
- Where
- 2 sites in India
- Volunteers
- 556 people
- Sponsor
- University of Geneva, Switzerland